Autopsy report · NCT04142060

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

“Lack of effectiveness”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 2 years 4 months before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

SOLTI Breast Cancer Research Group

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Enzalutamide

Participants

34

Sites

8

Countries

Spain

Trials that died the same way

• Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
  “lack of efficacy” (81% match in meaning)
• Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
  “lack of efficacy and lack of funding” (76% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (68% match in meaning)
• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (68% match in meaning)
• Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
  “Due to a lack of safety and efficacy.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.